Skip to main content

Table 2 Univariate and multivariate analyses for factors associated with overall survival of patients with intermediate to advanced HCC who received TACE with or without H101

From: Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study

Variable

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

PLT (vs. <100 × 109/L)

1.467 (0.993–2.166)

0.054

 

NI

ALT (vs. <40 U/L)

1.267 (0.993–1.617)

0.057

 

NI

AST (vs. <45 U/L)

2.037 (1.568–2.646)

<0.001

–

0.228

ALB (vs. <35 g/L)

0.704 (0.512–0.968)

0.031

–

0.424

TBIL (vs. <20 mmol/L)

1.213 (0.915–1.610)

0.180

 

NI

IBIL (vs. <15 mmol/L)

1.195 (0.809–1.765)

0.372

 

NI

ALP (vs. <100 U/L)

2.432 (1.859–3.180)

<0.001

1.494 (1.116–2.001)

0.007

CRP (vs. <8.2 mg/L)

2.180 (1.722–2.759)

<0.001

–

0.102

AFP (vs. <25 ng/mL)

1.547 (1.200–1.994)

0.001

1.389 (1.064–1.814)

0.016

HBsAg (vs. negative)

0.658 (0.413–1.048)

0.078

 

NI

HBV-DNA (vs. <100 IU/mL)

1.104 (0.876–1.392)

0.403

 

NI

NLR (vs. <3)

1.477 (1.145–1.904)

0.003

–

0.08

Tumor size (vs. <5 cm)

4.523 (3.156–6.481)

<0.001

3.120 (2.115–4.602)

<0.001

Tumor number (vs. single)

1.303 (1.019–1.668)

0.035

–

0.409

Splenomegaly (vs. no)

1.179 (0.928–1.499)

0.178

 

NI

Metastasis (vs. no)

3.668 (2.377–5.662)

<0.001

2.111 (1.342–3.321)

0.001

Vascular invasion (vs. no)

1.835 (1.443–2.335)

<0.001

1.292 (1.001–1.666)

0.049

Antiviral therapy (vs. no)

0.752 (0.596–0.950)

0.017

–

0.118

TACE (vs. without H101)

0.711 (0.563–0.896)

0.004

0.623 (0.492–0.789)

<0.001

  1. HR hazard ratio, CI confidence interval, NI not included. Other abbreviations as in Table 1
  2. – Data not shown due to no significance
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us